神经调节蛋白4调节脂代谢的研究进展

doi:10.16352/j.issn.1001-6325.2023.10.1599

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (10): 1599-1603.doi: 10.16352/j.issn.1001-6325.2023.10.1599

神经调节蛋白4调节脂代谢的研究进展

王雪冉, 田宗源, 刘瑞霞^*

首都医科大学附属北京妇产医院/北京妇幼保健院中心实验室, 北京 100026

收稿日期:2022-11-13 修回日期:2023-04-10 出版日期:2023-10-05 发布日期:2023-10-05
通讯作者: *liuruixia@ccmu.edu.cn
基金资助:
首都临床特色应用研究(Z181100001718076)

Research progress on neuregulin 4 regulating lipid metabolism

WANG Xueran, TIAN Zongyuan, LIU Ruixia^*

Department of Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing 100026, China

Received:2022-11-13 Revised:2023-04-10 Online:2023-10-05 Published:2023-10-05
Contact: *liuruixia@ccmu.edu.cn

摘要/Abstract

摘要： 神经调节蛋白4(NRG4)是一种新型脂肪分泌因子,主要在棕色脂肪表达及分泌。NRG4与肝细胞膜上表皮生长因子受体4(ErbB4)特异性结合,激活下游信号通路,抑制脂质的从头合成,增加脂肪酸氧化及生酮作用,减弱肝脂肪变性。NRG4还可调控脂肪组织基因的表达,降低脂肪细胞的胰岛素抵抗,调节脂肪组织中血管重塑,维持脂代谢平衡。NRG4对脂质的有益调节有助于改善与肥胖相关的代谢性紊乱,可能成为非酒精性脂肪肝、糖尿病和动脉粥样硬化等疾病的潜在治疗靶点。

关键词: 神经调节蛋白4, 脂代谢, 脂肪组织

Abstract: Neuregulin 4 (NRG4) is a novel fat secretion factor that is mainly expressed and secreted in brown fat. NRG4 specifically binds to epidermal growth factor receptor 4 (ErbB4) on hepatocyte membranes and activates downstream signaling pathways to relieve hepatic steatosis by inhibiting de novo synthesis of lipids, increasing fatty acid oxidation and ketogenesis. NRG4 can also regulate the expression of adipose tissue genes, reduce the insulin resistance of adipocytes, regulate vascular remodeling in adipose tissue, and benefit lipid metabolism. The favorable regulation of lipids by NRG4 may improve obesity-related metabolic disorders and might be a potential therapeutic target for metabolic diseases such as non-alcoholic fatty liver, diabetes, and atherosclerosis.

Key words: neuregulin 4(NRG4), lipid metabolism, adipose tissue

中图分类号:

王雪冉, 田宗源, 刘瑞霞. 神经调节蛋白4调节脂代谢的研究进展[J]. 基础医学与临床, 2023, 43(10): 1599-1603.

WANG Xueran, TIAN Zongyuan, LIU Ruixia. Research progress on neuregulin 4 regulating lipid metabolism[J]. Basic & Clinical Medicine, 2023, 43(10): 1599-1603.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2023.10.1599

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2023/V43/I10/1599

参考文献

[1]Harari D, Tzahar E, Romano J, et al. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase[J]. Oncogene, 1999, 18: 2681-2689.
[2]Wang GX, Zhao XY, Meng ZX, et al. The brown fat-enriched secreted factor Nrg4 preserves metabolic homeos-tasis through attenuation of hepatic lipogenesis[J]. Nat Med, 2014, 20: 1436-1443.
[3]Chen Z, Wang GX, Ma SL, et al. Nrg4 promotes fuel oxidation and a healthy adipokine profile to ameliorate diet-induced metabolic disorders[J]. Mol Metab, 2017, 6: 863-872.
[4]Zhu B, Mei W, Jiao T, et al. Neuregulin 4 alleviates hepatic steatosis via activating AMPK/mTOR-mediated autophagy in aged mice fed a high fat diet[J]. Eur J Pharmacol, 2020, 884: 173350. doi: 10.1016/j.ejphar.2020.173350.
[5]Wang H, Wang L, Hu F, et al. Neuregulin-4 attenuates diabetic cardiomyopathy by regulating autophagy via the AMPK/mTOR signalling pathway[J]. Cardiovasc Diabetol, 2022, 21: 205. doi: 10.1186/s12933-022-01643-0.
[6]Comas F, Martínez C, Sabater M, et al. Neuregulin 4 is a novel marker of beige adipocyte precursor cells in human adipose tissue[J]. Front Physiol, 2019, 10: 39. doi: 10.3389/fphys.2019.00039.
[7]Li Y, Jin L, Jiang F, et al. Mutations of NRG4 contribute to the pathogenesis of nonalcoholic fatty liver disease and related metabolic disorders[J]. Diabetes, 2021, 70: 2213-2224.
[8]Díaz-Sáez F, Blanco-Sinfreu C, Archilla-Ortega A, et al. Neuregulin 4 downregulation induces insulin resistance in 3T3-L1 adipocytes through inflammation and autophagic degradation of GLUT4 vesicles[J]. Int J Mol Sci, 2021, 22: 12960. doi: 10.3390/ijms222312960.
[9]Zhang L, Bai M, Tang H, et al. Role of hepatic neuregulin 4 in the regulation of gluconeogenesis in mice[J]. Life Sci, 2019, 217: 185-192.
[10]Martínez C, Latorre J, Ortega F, et al. Serum neuregulin 4 is negatively correlated with insulin sensitivity in humans and impairs mitochondrial respiration in HepG2 cells[J]. Front Physiol, 2022, 13: 950791. doi: 10.3389/fphys.2022.950791.
[11]Adachi Y, Ueda K, Nomura S, et al. Beiging of perivascular adipose tissue regulates its inflammation and vascular remodeling[J]. Nat Commun, 2022, 13: 5117. doi: 10.1038/s41467-022-32658-6.
[12]Shi L, Li Y, Xu X, et al. Brown adipose tissue-derived Nrg4 alleviates endothelial inflammation and athero-sclerosis in male mice[J]. Nat Metab, 2022, 4: 1573-1590.
[13]Guo L, Zhang P, Chen Z, et al. Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression[J]. J Clin Invest, 2017, 127: 4449-4461.
[14]De Munck TJI, Boesch M, Verhaegh P, et al. Is there a role for neuregulin 4 in human nonalcoholic fatty liver disease?[J]. PLoS One, 2021, 16: e0251822. doi: 10.1371/journal.pone.0251822.
[15]Tutunchi H, Mobasseri M, Aghamohammadzadeh N, et al. Serum neuregulin 4 (NRG-4) level and non-alcoholic fatty liver disease (NAFLD): a case-control study [J]. Int J Clin Pract, 2021, 75: e14555. doi: 10.1111/ijcp.14555.
[16]Cai C, Lin M, Xu Y, et al. Association of circulating neuregulin 4 with metabolic syndrome in obese adults: a cross-sectional study[J]. BMC Med, 2016, 14:165. doi: 10.1186/s12916-016-0703-6.
[17]Yan P, Xu Y, Wan Q, et al. Plasma neuregulin 4 levels are associated with metabolic syndrome in patients newly diagnosed with type 2 diabetes mellitus[J]. Dis Markers, 2018, 2018: 6974191. doi: 10.1155/2018/6974191.
[18]Guo D, Liu J, Zhang P, et al. Adiposity measurements and metabolic syndrome are linked through circulating neuregulin 4 and adipsin levels in obese adults[J]. Front Physiol, 2021, 12: 667330. doi: 10.3389/fphys.2021.667330.
[19]Li M, Chen Y, Jiang J, et al. Elevated serum neuregulin 4 levels in patients with hyperthyroidism[J]. Endocr Connect, 2019, 8: 728-735.
[20]魏巍, 张旭, 李婉娇, 等. 临床甲亢和亚临床甲亢患者血清Nrg4,TSK水平与血脂、甲状腺激素和基础代谢率的相关性分析[J]. 现代检验医学杂志, 2022, 37: 38-42+47.
[21]Li Q, Li C, Jin J, et al. Clinical significance of neuregulin 4, Afamin, and SERPINB1 in gestational diabetes mellitus and their relationship with insulin resistance[J]. Evid Based Complement Alternat Med, 2022, 2022: 2829662. doi: 10.1155/2022/2829662.
[22]Kralisch S, Hoffmann A, Kratzsch J, et al. The brown-fat-secreted adipokine neuregulin 4 is decreased in gestational diabetes mellitus[J]. Diabetes Metab, 2018, 44: 150-154.
[23]Zhang L, Lu B, Wang W, et al. Alteration of serum neuregulin 4 and neuregulin 1 in gestational diabetes mellitus[J]. Ther Adv Endocrinol Metab, 2021, 12: 20420188211049614. doi: 10.1177/20420188211049614.
[24]杨海荣, 丰树菊, 杜鹏琳, 等. 血清Spexin、神经调节蛋白4表达与妊娠期糖尿病的相关性[J]. 广东医学, 2021, 42: 1467-1471.
[25]高丽欣, 宋燕, 付凤仙. 妊娠期糖尿病患者血清神经调节蛋白4和Afamin水平变化及临床意义[J]. 中华实用诊断与治疗杂志, 2020, 34: 896-898.

神经调节蛋白4调节脂代谢的研究进展

Research progress on neuregulin 4 regulating lipid metabolism

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈辛, 陈俊, 徐幸, 王旭. 组蛋白去甲基化酶抑制剂GSK-J4减轻高脂诱导的肥胖小鼠体质量[J]. 基础医学与临床, 2023, 43(9): 1353-1358.
[2]	宋星明, 哈力沙·艾日肯江, 迪丽胡玛尔·阿布来提, 高颖. 内皮脂肪酶作为冠心病治疗靶点的研究进展[J]. 基础医学与临床, 2023, 43(9): 1443-1447.
[3]	李想, 李晔. 非酒精性脂肪性肝病中自噬与铁死亡相互作用的研究进展[J]. 基础医学与临床, 2023, 43(8): 1294-1298.
[4]	王星, 郭楠. 奥贝胆酸对高脂喂养的C57BL/6J小鼠糖脂稳态的影响[J]. 基础医学与临床, 2023, 43(5): 755-761.
[5]	杜丰禾, 刘暴. 血管周围脂肪组织炎性反应促进动脉粥样硬化作用机制的研究进展[J]. 基础医学与临床, 2023, 43(4): 685-689.
[6]	章远谋, 韩康, 夏瑞, 孙文健, 任晓莹, 王砚. 亚临床甲状腺功能减退症对多囊卵巢综合征患者内分泌代谢特征的影响[J]. 基础医学与临床, 2023, 43(4): 641-646.
[7]	王玉敏, 陈济超, 王洪权, 王金华, 唐博. MicroRNAs靶向脂代谢重编程参与肝细胞癌发生的研究进展[J]. 基础医学与临床, 2022, 42(12): 1930-1934.
[8]	黄婷, 李真真, 白杨, 刘惠双. 益生菌改善高脂高糖饲养诱导的肥胖小鼠脂代谢紊乱[J]. 基础医学与临床, 2021, 41(9): 1260-1265.
[9]	杨永, 李梓玉, 杨伟, 刘勇. 高脂饲养C57BL/6J小鼠肾周脂肪组织炎性反应的评估[J]. 基础医学与临床, 2021, 41(9): 1318-1322.
[10]	舒凤, 王梦伊, 张世武, 李倩竹, 张伟华. 脂肪组织炎性反应的研究进展[J]. 基础医学与临床, 2021, 41(7): 1052-1055.
[11]	张伟虹, 赵微, 李春美, 解相宏, 姚红, 刘晓军. 4,4'-二甲氧基查耳酮改善高脂饲养小鼠的胰岛素敏感性[J]. 基础医学与临床, 2021, 41(1): 77-81.
[12]	张唯舒婷宋小敏李博伦王婧. 敲除IgG受体FcγRIIB加重小鼠全身及脂肪组织炎性反应[J]. 基础医学与临床, 2018, 38(7): 938-943.
[13]	马池发史婷婷袁明霞. ACE/AngII/AT1轴和ACE2/Ang(1-7)/Mas轴对脂肪组织糖脂代谢的影响[J]. 基础医学与临床, 2018, 38(5): 708-712.
[14]	田清平唐朝枢庞永正刘梅林. Betatrophin是一种新的糖脂代谢影响因子[J]. 基础医学与临床, 2014, 34(11): 1570-1573.
[15]	杨华沈珠军. 脂肪来源细胞在缺血性心脏病中的应用[J]. 基础医学与临床, 2010, 30(11): 1226-1229.